Boston, MA 03\/25\/2014 (wallstreetpr) –\u00a0PAWS Pet Company Inc (OTCMKTS:PAWS)<\/b> is underway in its transition efforts. Having been largely in pet space, the company is transitioning to pharmaceuticals. With eminent changes in the traditional medical environment, the company is plotting to be in the right place at the right time in order to take advantage of opportunities as they come. And towards this end, the company which last reported revenue in September 2013, is making strategic acquisitions.<\/p>\n
The company in January announced closure of a deal with Mesa Pharmacy Inc. The move has been one reason of excitement in the stock as sales reports from Mesa have been very encouraging month after month. And as March sales report is expected out, investor confidence can be seen firming up in the stock of PAWS Pet Company.<\/p>\n
Share of the company rose more than 14 percent to $0.150 during Monday session. The gain came on the back of solid volume of shares changing hands. The Monday session saw shares shifting hands between $0.13 and $0.16. The shares traded in the range of $0.01 – $0.24 in the past year.<\/p>\n
In February, prescription sales at Mesa, a subsidiary of PAWS Pet Company Inc (OTCMKTS:PAWS), leaped in-line with expectation. The company reported that gross revenue in the month top $6.5 million, and said it was looking up to more growth in this month.<\/p>\n
Non-narcotic pain management<\/strong><\/p>\n <\/strong>Mesa provides non-narcotic pain medication, in this manner, the company is benefiting from the problems associated with narcotic medications and the laws that are limiting the use of narcotic-based treatments for pain. The company is having its trans-dermal pain formulations being popularly used in managing pain in injured workers and this has been a source of increasing sales. Mesa is also inking agreements with strategic partners to ensure that it grows its sales of non-narcotic pain formulations. According to the company\u2019s president Andrew Do, they are currently filling approximately $400,000 per day for their prescription pain medication.<\/p>\n It is the solid position which Mesa is increasingly moving into that has been seen pulling up the stock of PAWS Pet Company Inc (OTCMKTS:PAWS).<\/p>\n","protected":false},"excerpt":{"rendered":" Boston, MA 03\/25\/2014 (wallstreetpr) –\u00a0PAWS Pet Company Inc (OTCMKTS:PAWS) is underway in its transition efforts. Having been largely in pet space, the company is transitioning […]<\/p>\n","protected":false},"author":6,"featured_media":17947,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236],"tags":[5462,5461],"stock_ticker":[],"class_list":["post-17943","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-otcmktspaws","tag-paws-pet-company-inc-otcmktspaws","entry"],"acf":[],"yoast_head":"\n